Vunderkind
Social Member
Speculative buying at its finest. Sure, there isn't a cure for Ebola yet, but that's just it: there isn't any yet. As investors catch a whiff of the potential of the TKM-Ebola drug, the company has experienced a sweet lunge in shares.
From the PUNCH newspaper:
There is no cure for Ebola. But don’t tell that to traders. Shares of a US-based company working on a drug to treat the infectious disease surged nearly 40% last week.
Tekmira Pharmaceuticals popped on much higher trading volume than usual because investors are hopeful that health agencies in the United States might approve its drug, known as TKM-Ebola.
But investors buying this stock now need to be extremely careful.
CNN reported Monday that two Americans who were infected with the Ebola virus in Liberia were treated with a drug made by privately-held San Diego company Mapp Biopharmaceutical.
Click here to read more
Source: #PUNCH
From the PUNCH newspaper:
There is no cure for Ebola. But don’t tell that to traders. Shares of a US-based company working on a drug to treat the infectious disease surged nearly 40% last week.
Tekmira Pharmaceuticals popped on much higher trading volume than usual because investors are hopeful that health agencies in the United States might approve its drug, known as TKM-Ebola.
But investors buying this stock now need to be extremely careful.
CNN reported Monday that two Americans who were infected with the Ebola virus in Liberia were treated with a drug made by privately-held San Diego company Mapp Biopharmaceutical.
Click here to read more
Source: #PUNCH
